# Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile

> **NCT07455955** · PHASE2 · RECRUITING · sponsor: **Chinese University of Hong Kong** · enrollment: 200 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Standard antiemetic regimen or Olanzapine antiemetic regimen
- **DRUG:** Standard antiemetic regimen

## Key facts

- **NCT ID:** NCT07455955
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-31
- **Primary completion:** 2027-06-03
- **Final completion:** 2028-07-03
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07455955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07455955, "Personalized Antiemetic Regimen According to Patients' Pharmacogenetic Profile". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07455955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*